This analysis of real-world data shows increasing test use by year; however, one fifth of patients eligible for ALK testing still remain untested and potentially missing therapeutic options. READ ARTICLE
The Oncologist DOI:10.1002/onco.13779
Authors: Eric H Bernicker, Yan Xiao, DrPH, Anup Abraham MPH, Baiyu Yang, Denise Croix, Stella Redpath, Julia Engstrom-Melnyk, Roma Shah MPH, Jaya Madala MS, Timothey Craig Allen, JD
